{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:59:47Z","timestamp":1762865987251},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T00:00:00Z","timestamp":1337126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s00259-012-2145-5","type":"journal-article","created":{"date-parts":[[2012,5,15]],"date-time":"2012-05-15T09:03:07Z","timestamp":1337072587000},"page":"1306-1315","source":"Crossref","is-referenced-by-count":25,"title":["Hepatic artery injection of 131I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study"],"prefix":"10.1007","volume":"39","author":[{"given":"Lu","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye-Fa","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nai-Jian","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Qun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,16]]},"reference":[{"issue":"2","key":"2145_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69\u201390.","journal-title":"CA Cancer J Clin"},{"issue":"9664","key":"2145_CR2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(09)60381-0","volume":"373","author":"J Bruix","year":"2009","unstructured":"Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373(9664):614\u20136.","journal-title":"Lancet"},{"issue":"12","key":"2145_CR3","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","volume":"365","author":"HB El-Serag","year":"2011","unstructured":"El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118\u201327.","journal-title":"N Engl J Med"},{"issue":"2","key":"2145_CR4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429\u201342.","journal-title":"Hepatology"},{"issue":"Suppl 3","key":"2145_CR5","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1016\/S1590-8658(10)60513-0","volume":"42","author":"L Andreana","year":"2010","unstructured":"Andreana L, Burroughs AK. Treatment of early hepatocellular carcinoma: how to predict and prevent recurrence. Dig Liver Dis. 2010;42 Suppl 3:S249\u201357.","journal-title":"Dig Liver Dis"},{"issue":"12","key":"2145_CR6","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00259-002-0996-x","volume":"29","author":"ZC Zeng","year":"2002","unstructured":"Zeng ZC, Tang ZY, Yang BH, Liu KD, Wu ZQ, Fan J, et al. Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2002;29(12):1657\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"2145_CR7","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/cncr.21811","volume":"106","author":"MA Hawkins","year":"2006","unstructured":"Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer. 2006;106(8):1653\u201363.","journal-title":"Cancer"},{"issue":"4","key":"2145_CR8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.semradonc.2011.05.002","volume":"21","author":"M Feng","year":"2011","unstructured":"Feng M, Ben-Josef E. Radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol. 2011;21(4):271\u20137.","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"2145_CR9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.semradonc.2011.05.009","volume":"21","author":"LA Dawson","year":"2011","unstructured":"Dawson LA. Overview: where does radiation therapy fit in the spectrum of liver cancer local-regional therapies? Semin Radiat Oncol. 2011;21(4):241\u20136.","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"2145_CR10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijrobp.2005.12.034","volume":"65","author":"ZN Chen","year":"2006","unstructured":"Chen ZN, Mi L, Xu J, Song F, Zhang Q, Zhang Z, et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I)metuximab injection: clinical phase I\/II trials. Int J Radiat Oncol Biol Phys. 2006;65(2):435\u201344.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"20","key":"2145_CR11","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.1158\/1078-0432.CCR-11-0483","volume":"17","author":"M Steiner","year":"2011","unstructured":"Steiner M, Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res. 2011;17(20):6406\u201316.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2145_CR12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4161\/cbt.5.3.2431","volume":"5","author":"Z Zhang","year":"2006","unstructured":"Zhang Z, Bian H, Feng Q, Mi L, Mo T, Kuang A, et al. Biodistribution and localization of iodine-131-labeled metuximab in patients with hepatocellular carcinoma. Cancer Biol Ther. 2006;5(3):318\u201322.","journal-title":"Cancer Biol Ther"},{"key":"2145_CR13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0070-2153(03)54015-7","volume":"54","author":"BP Toole","year":"2003","unstructured":"Toole BP. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol. 2003;54:371\u201389.","journal-title":"Curr Top Dev Biol"},{"key":"2145_CR14","unstructured":"Chen ZN SP, Li Y, Qian AR, Zhu P, Xing JL, inventor; NTD Patent & Trademark Agency Ltd., Beijing office, assignee. HAb18G\/CD147, its agonist and application. Chinese 2001 Sep 28; PCT international patent WO02\/094875. 2002 May 27."},{"issue":"7","key":"2145_CR15","doi-asserted-by":"crossref","first-page":"808","DOI":"10.4161\/cbt.5.7.2754","volume":"5","author":"Q Zhang","year":"2006","unstructured":"Zhang Q, Chen X, Zhou J, Zhang L, Zhao Q, Chen G, et al. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther. 2006;5(7):808\u201314.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"2145_CR16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hep.21465","volume":"45","author":"J Xu","year":"2007","unstructured":"Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology. 2007;45(2):269\u201376.","journal-title":"Hepatology"},{"issue":"6","key":"2145_CR17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/cbr.2010.0801","volume":"25","author":"L Wu","year":"2010","unstructured":"Wu L, Yang YF, Ge NJ, Shen SQ, Liang J, Wang Y, et al. Hepatic arterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma: interim safety and survival data from 110 patients. Cancer Biother Radiopharm. 2010;25(6):657\u201363.","journal-title":"Cancer Biother Radiopharm"},{"issue":"3","key":"2145_CR18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","volume":"35","author":"J Bruix","year":"2001","unstructured":"Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35(3):421\u201330.","journal-title":"J Hepatol"},{"issue":"10","key":"2145_CR19","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","volume":"100","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698\u2013711.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2145_CR20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1572-0241.2006.00467.x","volume":"101","author":"A Colli","year":"2006","unstructured":"Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006;101(3):513\u201323.","journal-title":"Am J Gastroenterol"},{"issue":"9319","key":"2145_CR21","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734\u20139.","journal-title":"Lancet"},{"issue":"5","key":"2145_CR22","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/hep.24812","volume":"55","author":"S Senthilnathan","year":"2012","unstructured":"Senthilnathan S, Memon K, Lewandowski RJ, Kulik L, Mulcahy MF, Riaz A, et al. Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated by locoregional therapies: analyzing patterns of progression in 285 patients. Hepatology. 2012;55(5):1432\u201342","journal-title":"Hepatology"},{"issue":"3","key":"2145_CR23","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1148\/radiology.216.3.r00se24698","volume":"216","author":"S Katyal","year":"2000","unstructured":"Katyal S, Oliver 3rd JH, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000;216(3):698\u2013703.","journal-title":"Radiology"},{"key":"2145_CR24","unstructured":"Chen ZN XJ, Zhang SH, inventor; NTD Patent & Trademark Agency Ltd., Beijing office, assignee. Anti-human hepatoma monoclonal antibody HAb18 light\/heavy chain variable region gene, and use thereof. Chinese 2002 March 15; PCT international patent WO03\/078469. 2003 March 17."},{"issue":"1","key":"2145_CR25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207\u201314.","journal-title":"Cancer"},{"issue":"10","key":"2145_CR26","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.3748\/wjg.v9.i10.2174","volume":"9","author":"Y Li","year":"2003","unstructured":"Li Y, Shang P, Qian AR, Wang L, Yang Y, Chen ZN. Inhibitory effects of antisense RNA of HAb18G\/CD147 on invasion of hepatocellular carcinoma cells in vitro. World J Gastroenterol. 2003;9(10):2174\u20137.","journal-title":"World J Gastroenterol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-012-2145-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-012-2145-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-012-2145-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:05:22Z","timestamp":1558699522000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-012-2145-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,16]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["2145"],"URL":"https:\/\/doi.org\/10.1007\/s00259-012-2145-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,16]]}}}